P. P. Breitfeld and W. H. Meyer, Rhabdomyosarcoma: new windows of opportunity, vol.10, pp.518-527, 2005.

T. M. Dantonello, C. Int-veen, P. Winkler, I. Leuschner, A. Schuck et al., Initial patient characteristics can predict pattern and risk of relapse in localized rhabdomyosarcoma, J. Clin. Oncol, vol.26, pp.406-413, 2008.

R. B. Raney, H. M. Maurer, J. R. Anderson, R. J. Andrassy, S. S. Donaldson et al., The Intergroup Rhabdomyosarcoma Study Group (IRSG): major lessons from the IRS-I through IRS-IV studies as background for the current IRS-V treatment protocols, Sarcoma, vol.5, pp.9-15, 2001.

F. Ducimetiere, A. Lurkin, D. Ranchere-vince, A. V. Decouvelaere, M. Peoc'h et al., Incidence of sarcoma histotypes and molecular subtypes in a prospective, PLoS One, vol.6, p.20294, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00799650

D. Walterhouse and A. Watson, Optimal management strategies for rhabdomyosarcoma in children, Paediatr. Drugs, vol.9, pp.391-400, 2007.

H. M. Maurer, M. Beltangady, E. A. Gehan, W. Crist, D. Hammond et al., The intergroup rhabdomyosarcoma study-I. A final report, Cancer, vol.61, pp.209-220, 1988.

H. M. Maurer, E. A. Gehan, M. Beltangady, W. Crist, P. S. Dickman et al., The intergroup rhabdomyosarcoma study-II, Cancer, vol.71, pp.1904-1922, 1993.

W. Crist, E. A. Gehan, A. H. Ragab, P. S. Dickman, S. S. Donaldson et al., The third intergroup rhabdomyosarcoma study, J. Clin. Oncol, vol.13, pp.610-630, 1995.

W. M. Crist, J. R. Anderson, J. L. Meza, C. Fryer, R. B. Raney et al., Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease, J. Clin. Oncol, vol.19, pp.3091-3102, 2001.

M. C. Stevens, A. Rey, N. Bouvet, C. Ellershaw, F. Flamant et al., Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology-SIOP Malignant Mesenchymal Tumor 89, J. Clin. Oncol, vol.23, pp.2618-2628, 2005.

A. Ferrari, P. Dileo, M. Casanova, R. Bertulli, C. Meazza et al., Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution, Cancer, vol.98, pp.571-580, 2003.

D. J. Little, M. T. Ballo, G. K. Zagars, P. W. Pisters, S. R. Patel et al., Adult rhabdomyosarcoma: outcome following multimodality treatment, Cancer, vol.95, pp.377-388, 2002.

W. G. Hawkins, A. Hoos, C. R. Antonescu, M. J. Urist, D. H. Leung et al., Clinicopathologic analysis of patients with adult rhabdomyosarcoma, Cancer, vol.91, pp.794-803, 2001.

N. K. Gerber, L. H. Wexler, S. Singer, K. M. Alektiar, M. L. Keohan et al., Adult rhabdomyosarcoma survival improved with treatment on multimodality, Int. J. Radiat. Oncol. Biol. Phys, vol.86, pp.58-63, 2013.

S. N. Dumont, D. M. Araujo, M. F. Munsell, J. A. Salganick, A. G. Dumont et al., Management and outcome of 239 adolescent and adult rhabdomyosarcoma patients, Cancer Med, vol.2, pp.553-563, 2013.

N. F. Esnaola, B. P. Rubin, E. H. Baldini, N. Vasudevan, G. D. Demetri et al., Response to chemotherapy and predictors of survival in adult rhabdomyosarcoma, Ann. Surg, vol.234, pp.215-223, 2001.

L. Quaglia, M. P. , G. Heller, F. Ghavimi, E. S. Casper et al., The effect of age at diagnosis on outcome in rhabdomyosarcoma, Cancer, vol.73, pp.109-117, 1994.

J. Y. Blay, P. Soibinet, N. Penel, E. Bompas, F. Duffaud et al., Improved survival using specialized multidisciplinary board in sarcoma patients, Ann. Oncol, vol.28, pp.2852-2859, 2017.

R. V. Lloyd, S. I. Hajdu, and W. H. Knapper, Embryonal rhabdomyosarcoma in adults, Cancer, vol.51, pp.557-565, 1983.

M. Ben-arush, V. Minard-colin, V. Mosseri, A. S. Defachelles, C. Bergeron et al., , 2015.

, Rhabdomyosarcoma an Ambispective Study aggressive local treatment have an impact on survival in children with metastatic rhabdomyosarcoma?, Eur. J. Cancer, vol.51, pp.193-201

A. Gronchi, LBA6_PR -Full-dose neoadjuvant anthracycline + ifosfamide chemotherapy is associated with a relapse free survival (RFS) and overall survival (OS) benefit in localized high-risk adult soft tissue sarcomas (STS) of the extremities and trunk wall: Interim analysis of a prospective randomized trial, 2016.

A. Italiano, F. Delva, S. Mathoulin-pelissier, A. Le-cesne, S. Bonvalot et al., Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French Sarcoma Group Database, Ann. Oncol, vol.21, pp.2436-2441, 2010.

, Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration, Lancet, vol.350, pp.1647-1654, 1997.

N. Pervaiz, N. Colterjohn, F. Farrokhyar, R. Tozer, A. Figueredo et al., A systematic metaanalysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma, Cancer, vol.113, pp.573-581, 2008.

P. J. Woll, P. Reichardt, A. Le-cesne, S. Bonvalot, A. Azzarelli et al., Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial, Lancet Oncol, vol.13, pp.1045-1054, 2012.

P. G. Casali and J. Y. Blay, Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann. Oncol, vol.21, pp.198-203, 2010.

J. Y. Blay and A. Le-cesne, Adjuvant chemotherapy in localized soft tissue sarcomas: still not proven, Oncologist, vol.14, pp.1013-1020, 2009.

, Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann. Oncol, vol.25, issue.3, pp.102-112, 2014.

D. A. Rodeberg, C. N. Paidas, T. L. Lobe, K. Brown, R. J. Andrassy et al., Surgical principles for children/adolescents with newly diagnosed rhabdomyosarcoma: a report from the soft tissue sarcoma committee of the children's oncology group, Sarcoma, vol.6, pp.111-122, 2002.

R. J. Andrassy, C. A. Corpron, D. Hays, R. B. Raney, E. S. Wiener et al., Extremity sarcomas: an analysis of prognostic factors from the Intergroup Rhabdomyosarcoma Study III, J. Pediatr. Surg, vol.31, pp.191-196, 1996.

S. Bonvalot, C. P. Raut, R. E. Pollock, P. Rutkowski, D. C. Strauss et al., Technical considerations in surgery for retroperitoneal sarcomas: position paper from E-Surge, a master class in sarcoma surgery, and EORTC-STBSG, Ann. Surg. Oncol, vol.19, pp.2981-2991, 2012.

C. R. Rossi, A. Vecchiato, G. Mastrangelo, M. C. Montesco, F. Russano et al., Adherence to treatment guidelines for primary sarcomas affects patient survival: a side study of the European CONnective TIssue CAncer NETwork (CONTICANET), 2013.

, Ann. Oncol, vol.24, pp.1685-1691

E. Stoeckle, H. Gardet, J. M. Coindre, G. Kantor, F. Bonichon et al., Prospective evaluation of quality of surgery in soft tissue sarcoma, Eur. J. Surg. Oncol, vol.32, pp.1242-1248, 2006.

O. Derbel, C. Cropet, C. Meeus, F. Gilly, G. Vaz et al., Adhesion to clinical practices guidelines (CPGs) and role on survival for soft tissue sarcoma patients, 2012.

I. Ray-coquard, P. Thiesse, D. Ranchère-vince, F. Chauvin, J. Y. Bobin et al., Conformity to clinical practice guidelines, multidisciplinary management and outcome of treatment for soft tissue sarcomas, Ann Oncol, vol.15, pp.307-315, 2004.

C. A. Arndt and W. M. Crist, Common musculoskeletal tumors of childhood and adolescence, N. Engl. J. Med, vol.341, pp.342-352, 1999.

B. Raney, J. Anderson, J. Breneman, S. S. Donaldson, W. Huh et al., Results in patients with cranial parameningeal sarcoma and metastases (Stage 4) treated on intergroup rhabdomyosarcoma study group (IRSG) protocols II-IV, 1978-1997: report from the children's oncology group, Pediatr. Blood Cancer, vol.51, pp.17-22, 2008.

H. L. Neville, R. J. Andrassy, T. E. Lobe, C. E. Bagwell, J. R. Anderson et al., Preoperative staging, prognostic factors, and outcome for extremity rhabdomyosarcoma: a preliminary report from the Intergroup Rhabdomyosarcoma Study IV, vol.35, pp.317-321, 1991.

D. A. Rodeberg, N. Garcia-henriquez, E. R. Lyden, E. Davicioni, D. M. Parham et al., Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology Group, J. Clin. Oncol, vol.29, pp.1304-1311, 2011.

O. Oberlin, A. Rey, E. Lyden, G. Bisogno, M. C. Stevens et al., Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups, J. Clin. Oncol, vol.26, pp.2384-2389, 2008.

A. Rhabdomyosarcoma-an, E. Study, and . Bompas,

J. C. Breneman, E. Lyden, A. S. Pappo, M. P. Link, J. R. Anderson et al., Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma-a report from the Intergroup Rhabdomyosarcoma Study IV, J. Clin. Oncol, vol.21, pp.78-84, 2003.

P. Lagarde, J. Przybyl, C. Brulard, G. Pérot, G. Pierron et al., Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas, J. Clin. Oncol, vol.31, pp.608-615, 2013.

W. A. Newton, E. H. Soule, A. B. Hamoudi, H. M. Reiman, H. Shimada et al., Histopathology of childhood sarcomas, Intergroup Rhabdomyosarcoma Studies I and II: clinicopathologic correlation, J. Clin. Oncol, vol.6, pp.67-75, 1988.

W. A. Newton, E. A. Gehan, B. L. Webber, H. B. Marsden, A. J. Van-unnik et al., Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification-an Intergroup Rhabdomyosarcoma Study, Cancer, vol.76, pp.1073-1085, 1995.

J. L. Meza, J. Anderson, A. S. Pappo, and W. H. Meyer, Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group, J. Clin. Oncol, vol.24, pp.3844-3851, 2006.

T. M. Dantonello, C. Int-veen, D. Harms, I. Leuschner, B. F. Schmidt et al., Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults, J. Clin. Oncol, vol.27, pp.1446-1455, 2009.

D. Joshi, J. R. Anderson, C. Paidas, J. Breneman, D. M. Parham et al., Age is an independent prognostic factor in rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group, Pediatr. Blood Cancer, vol.42, pp.64-73, 2004.

S. Malempati and D. S. Hawkins, Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies, Pediatr. Blood Cancer, vol.59, pp.5-10, 2012.

C. A. Arndt, Risk stratification of rhabdomyosarcoma, Am Soc Clin Oncol Educ Book, vol.2013, pp.415-419, 2013.

R. B. Raney, D. O. Walterhouse, J. L. Meza, R. J. Andrassy, J. C. Breneman et al., Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group, J. Clin. Oncol, vol.29, pp.1312-1318, 2011.

O. Oberlin, A. Rey, J. Sanchez-de-toledo, H. Martelli, M. E. Jenney et al., Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study, J. Clin. Oncol, vol.30, pp.2457-2465, 2012.

C. Bergeron, P. Thiesse, A. Rey, D. Orbach, P. Boutard et al., Revisiting the role of doxorubicin in the treatment of rhabdomyosarcoma: an up-front window study in newly diagnosed children with high-risk metastatic disease, Eur. J. Cancer, vol.44, pp.427-431, 2008.

E. C. Van-dalen, M. F. Raphaël, H. N. Caron, and L. C. Kremer, Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer, Cochrane Database Syst. Rev. CD006647, 2009.